Revolution Medicines Delivers Strong KRAS Data at AACR
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Revolution Medicines unveiled robust Phase 2 data showing its KRAS inhibitor shrank tumors in a majority of KRAS‑mutant cancer patients, moving the candidate toward regulatory filing.
- AACR gathered in San Diego, where the opening ceremony featured a call for Congress to protect NIH funding amid ongoing budget battles.
- Margaret Foti condemned the administration’s $5 billion NIH cut proposal for FY 2027, labeling it “unacceptable” and urging the Senate Appropriations Committee to act.
- Trump has advanced a $5 billion reduction in the NIH budget for FY 2027, continuing his administration’s push to trim federal science spending.
- NIH received a budget increase for FY 2026 after Congress rejected earlier cuts, underscoring the political tug‑of‑war over research resources.
Why it matters: Revolution Medicines gains a clearer path to FDA approval as its KRAS inhibitor shows strong efficacy, while NIH research faces a $5 billion cut threat from Trump, risking delayed cancer breakthroughs and reduced U.S. scientific leadership.
Ask SkimNews
